A broad phase II study of cis-dichlorodiammineplatinum(II) was conducted. Eight patients with stage IVB Hodgkin's disease were studied. Four of these patients attained an objective partial remission of 7-19+ weeks' duration. The usual time to the occurence of a ≥25% response was 1 week. This drug is active in far-advanced Hodgkin's disease with a projected lower limit of response rate from 19% to 21%.
|Original language||English (US)|
|Number of pages||4|
|Journal||Cancer Treatment Reports|
|State||Published - 1979|